About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 97 record(s)
Req # A-2019-001863
Adverse Reaction Report (AER) for DEXILANT. Report numbers: E2B_02819319. AERs for ENTYVIO: E2B_02862257, E2B_02839118, 000731529, 000731158, E2B_02854153. AERs for VEDOLIZUMAB: E2B_02822017, E2B_02853524, E2B_02818273, E2B_02858723, E2B_02862064. AERs for ONDANSETRON: E2B_02829961, E2B_02829775, E2B_02841655, E2B_02861229, E2B_02826331, E2B_02837423, E2B_02860174, E2B_02861363, E2B_02861422, 000732064. AERs for PANTOPRAZOLE SODIUM: E2B_02820518, E2B_02837630, E2B_02820515, E2B_02829485, E2B_02819368. AERs for PANTOPRAZOLE: E2B_02820525, E2B_02821183, E2B_02851827, E2B_02831379, E2B_02835873, E2B_02855598, E2B_02865069, 000732053, E2B_02838948, E2B_02832091, 000731504, E2B_02828986, 000731073. AERs for TECTA: E2B_02861566, E2B_02856303. AER for PANTOPRAZOLE MAGNESIUM: E2B_02821386.Organization: Health Canada
January 2021
Req # A-2019-001997
Adverse Reaction Reports (AERs). Report numbers: 000723590, E2B_02394614, E2B_02221418, E2B_02313629, E2B_02313836, E2B_02313846, E2B_02313847, E2B_02388681, E2B_02398777, 000719561, 000721513, 000722240, E2B_02191232, E2B_02308896, E2B_023156424.Organization: Health Canada
January 2021
Req # A-2019-002011
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-100222-959.Organization: Health Canada
January 2021
Req # A-2020-000092
Adverse Reaction Reports (AERs) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02729184, E2B_02729251, E2B_02729430, E2B_02729442, E2B_02813060, E2B_02729474, E2B_02729483, E2B_02730157, E2B_02730689, E2B_02730879, E2B_02732254, E2B_02745952, E2B_02740982, E2B_02732422, E2B_02733864.Organization: Health Canada
January 2021
Req # A-2020-000115
Adverse Reaction Report (AER). Report number: E2B_02677382.Organization: Health Canada
January 2021
Req # A-2020-000135
Adverse Reaction Reports (AERs). Report numbers: E2B_02923798, E2B_02932860, E2B_02936877, E2B_02936939.Organization: Health Canada
January 2021
Req # A-2020-000143
Adverse Reaction Reports (AERs). Report numbers: E2B_02967245, E2B_02967381, E2B_02969820, E2B_02969837.Organization: Health Canada
January 2021
Req # A-2020-000227
Adverse Reaction Reports (AERs) for NUVARING. Report numbers: 000649134, 000651165, 000661554, 000663878, 000668358, 000676632, 000676923, 000678763, 000678799, 000663951, E2B_00693463, 000675696, 000675950.Organization: Health Canada
January 2021
Req # A-2020-000270
Adverse Reaction Reports (AERs). Report numbers: E2B_00502981, E2B_02671356, E2B_02942205, E2B_02810755, E2B_02818036 E2B_02112187, 000198439, E2B_02112186, E2B_02553043.Organization: Health Canada
January 2021
Req # A-2020-000304
Adverse Reaction Reports (AERs). Report numbers: E2B_00727845, E2B_02411169, E2B_02432542, E2B_02435687, E2B_02438883, E2B_02442631, E2B_02459999, E2B_02457426, E2B_02498329, E2B_02507282, E2B_02620278.Organization: Health Canada
January 2021